This study develops a compound, JMF4073, inhibiting thymidylate (TMP) and cytidylate (CMP) kinases, aiming for a new therapy against TKI-resistant CML. Here, EMP1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.